发生性夜间血红蛋白尿症 (PNH) 中的血栓形成:从发病到治疗
Styliani Kokoris1, Antri Polyviou2, Paschalis Evangelidis3
1Laboratory of Hematology and Blood Bank Unit, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
International journal of molecular sciences
|November 27, 2024
概括
性夜间血红蛋白尿 (PNH) 是一种罕见的疾病,导致贫血和危险的血栓. 像eculizumab这样的补充抑制剂对于治疗和预防PNH患者的这些血栓事件至关重要.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
背景情况:
- 性夜间血球蛋白尿症 (PNH) 是一种罕见的骨髓衰竭综合征.
- 关键特征包括溶血性贫血,血栓性事件 (TE) 和骨髓无形成症.
- 血栓形成会影响高达40%的PNH患者,通常发生在异常的静脉部位.
研究的目的:
- 审查PNH中血栓事件的发病因子.
- 讨论补充抑制剂在管理PNH相关血栓形成中的作用.
- 突出目前和新兴的PNH治疗策略.
主要方法:
- 关于PNH病原和治疗的科学文献的综述.
- 分析连接补充激活,血液溶解和血栓形成的机制.
- 评估补充抑制剂和抗凝固剂的临床疗效.
主要成果:
- 在PNH中,TEs是由补体激活,内皮功能障碍,血液溶解和血小板/中性粒细胞激活的复杂相互作用引起的.
- 在凝血,补充和炎症性细胞因子 (如IL-6) 之间存在积极的反循环.
- 补充抑制剂 (C5抑制剂) 已经改变了PNH护理,在治疗和预防TEs方面被证明是有效的.
结论:
- C5抑制剂对于血栓形成的PNH患者至关重要,并作为对TEs的预防措施.
- 对于经历TEs的PNH患者,建议使用抗凝剂进行联合治疗.
- 新型补充抑制剂为外血管或突破性血液溶解患者提供了替代方案.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Disorders of Hemostasis
710
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
710
Extrinsic and Intrinsic Pathways of Hemostasis
5.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.6K
Introduction to Hemostasis
5.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.7K
Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
172
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
172


